Able Biolabs’ capabilities encompass the full range of preclinical research needs. We have non-GLP in-house facilities and work with trusted partners to support GLP activities. Whether you’re developing a new drug or a consumer product, we generate the necessary scientific validation to support your needs.

Our team of PhD-level scientists can perform previously validated protocols or work with you to develop and refine models based on both parties’ shared expertise. Our process is transparent and collaborative in order to best facilitate the progress of your research program.

• 

  In vitro and ex vivo models

  We leverage traditional cell-based models as well as ex vivo approaches such as air-liquid interface and organoids to support your initial proof of concept work

  • Traditional cell culture models
  • Primary human cells
  • Organoids
  • Air-liquid interface (ALI)
• 

  In vivo models

  Drug assets can be tested for therapeutic or preventative activity using any route of administration.

  • Exposure/induced models
  • Humanized animal models
  • Germ-free

  Our team has particular expertise in chronic and infectious respiratory disease models:

  • Chronic disease – COPD, BPD, IPF, asthma, acute lung injury, PAH, CF
  • Infectious disease – COVID, RSV, viral infection, fungal infection
• 

  Custom models

  For models that are not “out of the box,” we offer support in developing and validating protocols. Contact us to start a discussion about your specific needs.

  • Rare disease
  • Transgenic animal models